Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290951 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT02290951 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 200 participants.
The verdict
NCT02290951, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.
Interventions
- DRUG Odronextamab multiple dose levels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-01-09 |
| Est. Completion | 2025-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290951
The ClinicalTrials.gov registry entry for NCT02290951 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Odronextamab multiple dose levels is the first listed.
NCT02290951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02290951 about?
NCT02290951 is a clinical study titled "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies". This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of prot...
What is the current status of trial NCT02290951?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2015-01-09. Estimated completion is 2025-08-21.
What interventions are being tested in trial NCT02290951?
The interventions under investigation include: Odronextamab multiple dose levels (DRUG).
Who is sponsoring clinical trial NCT02290951?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.